No abstract

An emerging body of evidence suggests that the coronavirus disease 2019 (COVID-19) may predispose patients to venous thromboembolism (VTE). Increased levels of D-dimer are associated with a worsening condition of the patient. Risk assessment for VTE in all patients with COVID-19 admitted to hospital is recommended.

No abstract

Progress in the treatment of Chronic Myeloid Leukaemia (CML) has significantly improved the survival rates and prognosis of these patients. As a result, there is a growing awareness of the adverse effects that the treatments used can have on the Cardiovascular (CV) system. A high percentage of patients develop sequential resistance to CML treatments and, in these cases, ponatinib represents a good therapeutic option that has been associated with cardiovascular events. This required the development of recommendations for its management. A Delphi analysis conducted by a multidisciplinary panel of experts developed and agreed on clinical practice recommendations to optimize cardiovascular risk control in CML patients requiring ponatinib treatment.